Topical Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis

• Status: Completed
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if lidocaine is effective in reducing the incidence of post-ERCP pancreatitis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abraham Mathew MD
• Collaborator: Milton S. Hershey Medical Center
• Treatments: Lidocaine

Criteria

Inclusion Criteria:

• Patients included are >18 years old, referred to Endoscopy Clinic for an ERCP for any well established indication such as: biliary strictures, benign and malignant hepato-pancreato-biliary tumors, chronic pancreatitis, and suspected sphincter of Oddi dysfunction

Exclusion Criteria:

• Known sensitivity to lidocaine or contrast agent

• History of seizure disorder

• History of cardiac arrhythmia (tachyarrhythmia, bradyarrhythmia, cardiac conduction defects, prolonged QT syndrome)

• History of congestive heart failure

• Active acute pancreatitis before procedure

• Planned biliary stent removal without pancreatogram

• Pregnancy

• Incarcerated individuals

• Less than 18 years of age

• Previous sphincterotomy

• Inability to give informed consent